The star of Abbvie Inc.'s multibillion-dollar acquisition of Stemcentrx Inc., rovalpituzumab tesirine (Rova-T), is officially dead after an interim analysis of the phase III Meru study found it failing to help people with advanced small-cell lung cancer (SCLC) live any longer than a placebo. Abbvie is terminating all further R&D of the disappointing asset.